Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.
Director Sells GKOS 15,000 Shares for $1.9 Million This ophthalmic device maker, focused on glaucoma solutions, reported a notable insider sale after a challenging year for its stock.
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday The company's recent past featured robust growth, and it anticipates continued rises into the near future.
Get insights into the top gainers and losers of Thursday's pre-market session. The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Why Glaukos Stock Jumped Over 20% After-Hours Today Glaukos shares surged 21% in after-hours trading after the company posted record third-quarter revenue and raised its full-year guidance.
What's going on in today's after hours session The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.
Glaukos Corp (NYSE:GKOS) Soars on Strong Q3 2025 Earnings Beat and Robust 2026 Outlook Glaukos (GKOS) smashed Q3 2025 earnings forecasts, sending its stock soaring. The company posted record revenue and raised its 2025 and 2026 sales guidance.
